Mozobil (Plerixafor)

Plerixafor, the active ingredient in Mozobil, is a CXCR4 antagonist presented as a 0.24 mg/mL injection solution for subcutaneous use. It facilitates the mobilization of hematopoietic stem cells into peripheral blood, enabling autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma.

GNH USA supplies Mozobil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mozobil (plerixafor) is employed to mobilize hematopoietic stem cells in hematologic malignancies.

- Non‑Hodgkin lymphoma: enhances peripheral blood stem cell collection for autologous transplantation. - Multiple myeloma: promotes stem cell release to support autologous transplant procedures. - Other eligible hematologic cancers: enables stem cell harvesting for autologous transplant as determined by the treating physician.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Injection site reactions: redness, swelling, or pain at the subcutaneous site. - Diarrhea: loose stools occurring shortly after administration. - Fatigue: transient tiredness reported by some patients. - Headache: mild to moderate intensity. - Dizziness: occasional sensation of light‑headedness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of breathing difficulty, swelling, or rash. - Splenic rupture: rare but potentially life‑threatening abdominal pain. - Severe hypotension: marked drop in blood pressure requiring medical attention. - Acute leukocytosis: sudden increase in white blood cell count.

Before using Mozobil, clinicians should consider several safety measures.

- Assess eligibility: confirm that autologous stem cell mobilization is indicated for the patient. - Monitor blood counts: observe hematologic parameters before and after administration. - Evaluate hypersensitivity: check for known allergy to plerixafor or formulation components. - Cardiovascular caution: avoid in patients with uncontrolled hypertension or severe cardiac disease. - Use in experienced centers: administer under supervision of a transplant‑qualified team. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Plerixafor may interact with other agents that affect stem cell mobilization or immune function.

Major Interactions (Avoid): - Concurrent CXCR4 antagonists: may lead to excessive stem cell release. - Unsupervised combination with high‑dose chemotherapy: increases risk of severe toxicity. - Use with investigational agents targeting SDF‑1/CXCR4 pathway without guidance.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding tendencies. - Antihistamines: may mask early signs of allergic reactions. - Other immunomodulators: observe for altered immune response.